Short-Term Effects of Intramuscular and Transdermal Testosterone on Bone Turnover, Prostate Symptoms, Cholesterol, and Hematocrit in Men Over Age 70 with Low Testosterone Levels

References

• Tenover JL. Testosterone and the Aging Male. J Andrology 1997; 18: 103–106
   PubMed Web of Science ®Google Scholar
• Isaia G., Mussetta M., Pecchio F., Sciolla A., di Stefano M., Molinatti G. M. Effect of testosterone on bone in hypogonadal males. Maturitas 1992; 15: 47–51
   PubMed Web of Science ®Google Scholar
• Finkelstein J. S., Klibanski A., Neer R. M., Greenspan S. L., Rosenthal D. L., Crowley W. F. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Int Med 1987; 106: 354–361
   PubMed Web of Science ®Google Scholar
• Slemenda C. W., Longcope C., Zhou L., Hui S. L., Peacock M., Johnston C. Sex steroids and bone mass in older men: Positive association with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100: 1755–1759
   PubMed Web of Science ®Google Scholar
• Center J. R., Ngugen T. V., White C. P., Eisman J. A. Male osteoporosis predictors: Sex hormones and calcitropic hormones. J Bone Miner Res 1997; 12: S368
   Web of Science ®Google Scholar
• Khosla S., Melton U, 3rd, Atkinson E. J., O'Fallon W. M., Klee G. G., Riggs B. L. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83(7)2266–2274
   PubMed Web of Science ®Google Scholar
• Greendale G. A., Edelstein S., Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo study. J Bone Miner Res 1997; 12: 1833–1843
   PubMed Web of Science ®Google Scholar
• Morley J. E., Kaiser F. E., Sih R., Hajar R., Perry H. M. Testosterone and frailty. Clinics in Geriatric Medicine 1997; 13: 685–695
   PubMed Web of Science ®Google Scholar
• Snyder P. J., Lawrence D. A. Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 1980; 51: 1336–1339
   Web of Science ®Google Scholar
• Meikle A. W., Mazer N. A., Moellmer J. F., Stringharn J. D., Tolman K. G., Sanders S. W., Odell W. D. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 1992; 74: 623–628
   PubMed Web of Science ®Google Scholar
• Meikle A. W., Annand D., Hunter C., Caramelli K. E., Daugherty C. A., John V. A., Mazer N. A. Pretreatment with a topical corticosteroid cream improves local tolerability and does not significantly alter the pharmacokinetics of the androderm testosterone transdermal system in hypogonadal men. The Annual Meeting of the Endocrine Society. 1997
   Google Scholar
• Smith E. P., Boyd J., Frank G. R., Takahashi H., Cohen R. M., Specker B., Williams T. C., Lubahn D. B., Korach K. S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. New Engl J Med 1994; 331: 1056–1061
   PubMed Web of Science ®Google Scholar
• Morishima A., Grumbach M. M., Simpson E. R., Fisher C., Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689–3698
   PubMed Web of Science ®Google Scholar
• Riggs B. L., Khosla S., Melton U. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998; 13: 763–773
   PubMed Web of Science ®Google Scholar
• Cummings S. R., Browner W. S., Bauer D., Stone K., Ensrud K., Jamal S., Ettinger B. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998; 339(11)733–738
   PubMed Web of Science ®Google Scholar
• Morley J. E., Perry HM, 3d, Kaiser F. E., Kraenzie D., Jensen J., Houston K., Mattammal M., Perry HM, Jr. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41(2)149–152
   PubMed Web of Science ®Google Scholar
• Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75(4)1092–1098
   PubMed Web of Science ®Google Scholar
• Snyder P. J., Peachey H., Hannoush P., Berlin J. A., Loh L., Holmes J. H., Dlewati A., Staley J., Santanna J., Kapoor S. C., Attie M. F., Haddad J. G., Strom B. L. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Med Endocrinol 1999; 84: 1966–1972
   PubMed Web of Science ®Google Scholar
• Jackson J. A., Waxman J., Spiekerman A. M. Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989; 149: 2365–2366
   PubMedGoogle Scholar
• Sandeman TF. The possible dangers of androgens for male climacteric. Med J Aust 1975; 1: 634–635
   PubMed Web of Science ®Google Scholar
• Guinan P. D., Dadoughi W., Alsheik H., Ablin R. F., Alrenga D., Bush I. M. Impotence therapy and cancer of the prostate. Am J Surg 1976; 131: 599–600
   PubMed Web of Science ®Google Scholar
• Pobers A, Essenhigh DM. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet 1986; 2: 742
   Web of Science ®Google Scholar
• Gann P. H., Hennekens C. H., Ma J., Longcope C., Stampfer M. J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118–1126
   PubMed Web of Science ®Google Scholar
• Carter H B, Pearson J. D., Metter E. J., Chan D. W., Andres R., Fozard J L., Rosner W., Walsh P. C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995; 27: 25–31
   PubMed Web of Science ®Google Scholar
• Orwoll E., Biddle J., Oviatt S. Transdermal testosterone supplementation in normal older men. Clin Res 1992; 40(1)95A
   Google Scholar
• Hurley B. F., Seals D. R., Hagberg J. M., Goldberg A. C., Cistrove S. M., Holloszy J. O., Wiest W. G., Goldberg A. P. High-density-lipoprotein cholesterol in bodybuilders vs. powerlifters. JAMA 1984; 252(4)507–513
   PubMed Web of Science ®Google Scholar
• Bagatell C. J., Knopp R. H., Vale W. W., Rivier J. E., Bremner W. J. Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Int Med 1992; 116(12)967–973
   PubMed Web of Science ®Google Scholar
• Friedl K. E., Hannan CJ, Jr, Jones R. E., Plymate S. R. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39(1)69–74
   PubMed Web of Science ®Google Scholar
• Dobson A. S., Meikle A. W., Arver S., Sanders S. W., Caramelli K. E., Mazer N. M. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999; 84: 3469–3478
   PubMed Web of Science ®Google Scholar